V Wealth Advisors LLC trimmed its holdings in Iqvia Holdings Inc (NYSE:IQV) by 13.4% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,945 shares of the medical research company’s stock after selling 300 shares during the quarter. V Wealth Advisors LLC’s holdings in Iqvia were worth $276,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Fortis Advisors LLC bought a new stake in shares of Iqvia in the 1st quarter worth approximately $32,000. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Iqvia by 46.0% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 308 shares of the medical research company’s stock worth $33,000 after acquiring an additional 97 shares during the last quarter. Carroll Financial Associates Inc. lifted its holdings in shares of Iqvia by 90.3% in the 2nd quarter. Carroll Financial Associates Inc. now owns 236 shares of the medical research company’s stock worth $33,000 after acquiring an additional 112 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in shares of Iqvia in the 2nd quarter worth approximately $35,000. Finally, Citizens Financial Group Inc RI lifted its holdings in shares of Iqvia by 69.4% in the 1st quarter. Citizens Financial Group Inc RI now owns 376 shares of the medical research company’s stock worth $41,000 after acquiring an additional 154 shares during the last quarter. Hedge funds and other institutional investors own 88.49% of the company’s stock.
A number of brokerages have recently weighed in on IQV. Wells Fargo & Co boosted their price objective on shares of Iqvia from $155.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. SunTrust Banks lifted their target price on shares of Iqvia from $128.00 to $172.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Deutsche Bank lifted their target price on shares of Iqvia from $145.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, July 23rd. Stephens assumed coverage on shares of Iqvia in a research note on Monday, July 6th. They issued an “equal weight” rating and a $150.00 target price on the stock. Finally, TheStreet downgraded shares of Iqvia from a “b-” rating to a “c” rating in a research note on Wednesday, July 22nd. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Iqvia has a consensus rating of “Buy” and a consensus price target of $165.11.
In other news, Director Group Holdings (Sbs) Advis Tpg sold 2,919,051 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $159.12, for a total value of $464,479,395.12. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Ari Bousbib sold 46,080 shares of the company’s stock in a transaction dated Wednesday, July 22nd. The stock was sold at an average price of $160.00, for a total transaction of $7,372,800.00. Following the completion of the sale, the insider now directly owns 698,115 shares in the company, valued at $111,698,400. The disclosure for this sale can be found here. Insiders sold a total of 2,984,574 shares of company stock worth $474,768,645 over the last ninety days. Insiders own 6.00% of the company’s stock.
Shares of Iqvia stock opened at $158.39 on Friday. The company has a current ratio of 1.10, a quick ratio of 1.09 and a debt-to-equity ratio of 2.11. The company’s fifty day simple moving average is $145.51 and its two-hundred day simple moving average is $140.52. The company has a market cap of $30.30 billion, a P/E ratio of 232.93, a PEG ratio of 2.80 and a beta of 1.32. Iqvia Holdings Inc has a 12-month low of $81.79 and a 12-month high of $169.14.
Iqvia (NYSE:IQV) last issued its quarterly earnings data on Wednesday, July 22nd. The medical research company reported $1.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. The business had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.41 billion. Iqvia had a net margin of 1.21% and a return on equity of 17.90%. During the same period in the previous year, the firm earned $1.53 EPS. Analysts predict that Iqvia Holdings Inc will post 5.72 EPS for the current fiscal year.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More: What is the definition of arbitrage?
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.